A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: Interplay between CYP3A gut wall metabolism, permeability and dissolution

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 7, 2012, Pages 1008-1024

  Darwich, Adam S ^a   Pade, Devendra ^c   Ammori, Basil J ^b,d   Jamei, Masoud ^c   Ashcroft, Darren M ^a   Rostami Hodjegan, Amin ^a,c  

^a Department of Clinical Biochemistry   (Iran)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CERTARA UK LIMITED   (United Kingdom)

^d HOPE HOSPITAL   (United Kingdom)

Author keywords

ADAM model; bariatric surgery; obesity; oral drug bioavailability; pharmacokinetic modelling

Indexed keywords

CIPROFLOXACIN; CYTOCHROME P450 3A; DICLOFENAC; FLUCONAZOLE; OMEPRAZOLE; SIMVASTATIN;

ARTICLE; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; COMPUTER MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; HUMAN TISSUE; JEJUNOILEAL BYPASS; KIDNEY FUNCTION; MORBID OBESITY; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; SMALL INTESTINE; STOMACH BYPASS; STOMACH EMPTYING; SURGICAL TECHNIQUE;

ADMINISTRATION, ORAL; BARIATRIC SURGERY; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CIPROFLOXACIN; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; DICLOFENAC; FLUCONAZOLE; HUMANS; INTESTINAL MUCOSA; MODELS, BIOLOGICAL; OBESITY, MORBID; OMEPRAZOLE; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SIMVASTATIN; SOLUBILITY;

EID: 84862164070     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01538.x     Document Type: Article

References (87)

1. Flegal KM, et al,. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
2. Organisation for Economic Co-operation and Development Obesity and the Economics of Prevention: Fit Not Fat-United Kingdom (England) Key Facts. Paris: Organisation for Economic Co-operation and Development, 2011. (accessed January 17 2012).
3. Ammori BJ,. Laparoscopic Sleeve Gastrectomy. Manchester: Laparoscopic Obesity Surgery Experts, 2012. (accessed April 2 2012).
4. Elder KA, Wolfe BM,. Bariatric surgery: a review of procedures and outcomes. Gastroenterology 2007; 132: 2253-2271. (Pubitemid 46693754)
5. Buchwald H, Oien DM,. Metabolic/bariatric surgery worldwide 2008. Obes Surg 2009; 19: 1605-1611.
6. Picot J, et al,. The clinical effectiveness and cost effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 2009; 13: 23-77.
7. Schneider BE, Mun EC,. Surgical management of morbid obesity. Diabetes Care 2005; 28: 475-480. (Pubitemid 40173990)
8. Lee CM, et al,. Vertical gastrectomy for morbid obesity in 216 patients: report of two-year results. Surg Endosc 2007; 21: 1810-1816. (Pubitemid 47404119)
9. National Institute of Diabetes and Digestive and Kidney Diseases. Bariatric Surgery for Severe Obesity. Bethesda, MD: National Institutes of Health, 2010: (accessed November 9 2012).
10. Griffen WO Jr, et al,. A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg 1977; 186: 500-509. (Pubitemid 8197682)
11. Singh D, et al,. Jejunoileal bypass: a surgery of the past and a review of its complications. World J Gastroenterol 2009; 15: 2277-2279.
12. Darwich AS, et al,. Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. Br J Clin Pharmacol 2012. [Epub ahead of print]
13. Rowland M, Tozer TN,. Clinical Pharmacokinetics: Concepts and Applications, 2nd edn. Philadelphia: Lea & Febiger, 1989.
14. Jamei M, et al,. Population-based mechanistic prediction of oral drug absorption. AAPS J 2009; 11: 225-237.
15. Higaki K, et al,. Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans. Eur J Pharm Biopharm 2008; 70: 313-325.
16. Blum RA, et al,. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991; 114: 755-757.
17. Avdeef A,. Solubility of sparingly-soluble ionizable drugs. Adv Drug Deliv Rev 2007; 59: 568-590. (Pubitemid 47285405)
18. Koch KM, et al,. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time. Pharm Res 1993; 10: 1027-1030. (Pubitemid 23211427)
19. Kolars JC, et al,. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4: 247-259. (Pubitemid 24337433)
20. Peters WH, et al,. Human intestinal glutathione S-transferases. Biochem J 1989; 257: 471-476. (Pubitemid 19040920)
21. Fisher MB, et al,. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 2001; 33: 273-297. (Pubitemid 33136266)
22. Paine MF, et al,. The human intestinal cytochrome P450 'pie'. Drug Metab Dispos 2006; 34: 880-886.
23. Riches Z, et al,. Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT 'pie'. Drug Metab Dispos 2009; 37: 2255-2261.
24. Paine MF, et al,. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 1552-1562. (Pubitemid 28016533)
25. Benet LZ, Cummins CL,. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 2001; 50 (Suppl.): 1S3-111.
26. Darwich AS, et al,. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the 'advanced dissolution, absorption, metabolism (ADAM)' model. Curr Drug Metab 2010; 11: 716-729.
27. Fromm MF, et al,. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000; 157: 1575-1580.
28. Maliepaard M, et al,. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61: 3458-3464. (Pubitemid 32695041)
29. Mouly S, Paine MF,. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003; 20: 1595-1599. (Pubitemid 37268274)
30. Jamei M, et al,. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009; 5: 211-223.
31. Huang W, et al,. Mechanistic approaches to predicting oral drug absorption. AAPS J 2009; 11: 217-224.
32. Agoram B, et al,. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001; 50 (Suppl. 1): S41-S67. (Pubitemid 32905355)
33. Ghobadi C, et al,. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin Pharmacokinet 2011; 50: 809-822.
34. Delgado-Aros S, et al,. Independent influences of body mass and gastric volumes on satiation in humans. Gastroenterology 2004; 126: 432-440. (Pubitemid 38182300)
35. Valentin J,. Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. ICRP Publication, 89, Oxford: International Commission on Radiological Protection, Pergamon, 2002.
36. Turner D,. Simcyp User Manual Version 8, 8 edn. Sheffield: Simcyp Limited, 2008.
37. Wittgrove AC, Clark GW,. Laparoscopic gastric bypass, Roux-en-Y- 500 patients: technique and results, with 3-60 month follow-up. Obes Surg 2000; 10: 233-239.
38. Smith CD, et al,. Gastric acid secretion and vitamin B12 absorption after vertical Roux-en-Y gastric bypass for morbid obesity. Ann Surg 1993; 218: 91-96. (Pubitemid 23215198)
39. Behrns KE, et al,. Prospective evaluation of gastric acid secretion and cobalamin absorption following gastric bypass for clinically severe obesity. Dig Dis Sci 1994; 39: 315-320. (Pubitemid 24073606)
40. Braghetto I, et al,. Scintigraphic evaluation of gastric emptying in obese patients submitted to sleeve gastrectomy compared to normal subjects. Obes Surg 2009; 19: 1515-1521.
41. Hinder RA, et al,. Management of gastric emptying disorders following the Roux-en-Y procedure. Surgery 1988; 104: 765-772.
42. Horowitz M, et al,. Measurement of gastric emptying after gastric bypass surgery using radionuclides. Br J Surg 1982; 69: 655-657. (Pubitemid 13232187)
43. Rieu PN, et al,. Gastric emptying after partial gastrectomy without vagotomy with primary Roux-en-Y or Billroth II anastomosis. Nucl Med Commun 1989; 10: 715-722. (Pubitemid 19260215)
44. Shah S, et al,. Prospective controlled study of effect of laparoscopic sleeve gastrectomy on small bowel transit time and gastric emptying half-time in morbidly obese patients with type 2 diabetes mellitus. Surg Obes Relat Dis 2010; 6: 152-157.
45. Petrakis J, et al,. Enhancement of gastric emptying of solids by erythromycin in patients with Roux-en-Y gastrojejunostomy. Arch Surg 1998; 133: 709-714. (Pubitemid 28324149)
46. Bernstine H, et al,. Gastric emptying is not affected by sleeve gastrectomy-scintigraphic evaluation of gastric emptying after sleeve gastrectomy without removal of the gastric antrum. Obes Surg 2009; 19: 293-298.
47. Spak E, et al,. Changes in the mucosa of the Roux-limb after gastric bypass surgery. Histopathology 2010; 57: 680-688.
48. Demaria EJ, et al,. Results of 281 consecutive total laparoscopic Roux-en-Y gastric bypasses to treat morbid obesity. Ann Surg 2002; 235: 640-645. discussion 645-647.
49. Skottheim IB, et al,. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin Pharmacol Ther 2009; 86: 311-318.
50. Pellegrini CA, et al,. Intestinal transit of food after total gastrectomy and Roux-Y esophagojejunostomy. Am J Surg 1986; 151: 117-125. (Pubitemid 16143192)
51. Haglund U, et al,. Esophageal and jejunal motor function after total gastrectomy and Roux-Y esophagojejunostomy. Am J Surg 1989; 157: 308-311. (Pubitemid 19074560)
52. Le Blanc-Louvry I, et al,. Roux-en-Y limb motility after total or distal gastrectomy in symptomatic and asymptomatic patients. J Am Coll Surg 2000; 190: 408-417. (Pubitemid 30181106)
53. Van Der Mijle HC, et al,. Manometric and scintigraphic studies of the relation between motility disturbances in the Roux limb and the Roux-en-Y syndrome. Am J Surg 1993; 166: 11-17.
54. Woodward A, et al,. Gastric stasis of solids after Roux gastrectomy: is the jejunal transection important? J Surg Res 1993; 55: 317-322. (Pubitemid 23346869)
55. Le Blanc-Louvry I, et al,. Motility in the Roux-Y limb after distal gastrectomy: relation to the length of the limb and the afferent duodenojejunal segment-an experimental study. Neurogastroenterol Motil 1999; 11: 365-374. (Pubitemid 29410637)
56. Suzuki S, et al,. Changes in GI hormones and their effect on gastric emptying and transit times after Roux-en-Y gastric bypass in rat model. Surgery 2005; 138: 283-290.
57. Baltasar A, et al,. Laparoscopic sleeve gastrectomy: a multi-purpose bariatric operation. Obes Surg 2005; 15: 1124-1128. (Pubitemid 41390208)
58. Scott HW Jr, et al,. Considerations in use of jejunoileal bypass in patients with morbid obesity. Ann Surg 1973; 177: 723-735.
59. Scott HW Jr, et al,. Experience with a new technic of intestinal bypass in the treatment of morbid obesity. Ann Surg 1971; 174: 560-572.
60. Saliba J, et al,. Roux-en-Y gastric bypass reverses renal glomerular but not tubular abnormalities in excessively obese diabetics. Surgery 2010; 147: 282-287.
61. Chagnac A, et al,. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003; 14: 1480-1486. (Pubitemid 36687049)
62. Navarro-Diaz M, et al,. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol 2006; 17 (Suppl. 3): S213-S217. (Pubitemid 44865251)
63. Serra A, et al,. The effect of bariatric surgery on adipocytokines, renal parameters and other cardiovascular risk factors in severe and very severe obesity: 1-year follow-up. Clin Nutr 2006; 25: 400-408. (Pubitemid 44182760)
64. Michels WM, et al,. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 2010; 5: 1003-1009.
65. Benedek IH, et al,. Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 1984; 18: 941-946. (Pubitemid 15190533)
66. Mattar SG, et al,. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005; 242: 610-617. discussion 618-620.
67. Stratopoulos C, et al,. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 2005; 15: 1154-1160. (Pubitemid 41390214)
68. Barker KB, et al,. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006; 101: 368-373. (Pubitemid 43381682)
69. Van Dielen FM, et al,. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J Clin Endocrinol Metab 2004; 89: 4062-4068. (Pubitemid 39071514)
70. Johnson TN, et al,. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl 2005; 11: 1481-1493. (Pubitemid 43072624)
71. Howgate EM, et al,. Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica 2006; 36: 473-497. (Pubitemid 43890728)
72. Benet LZ, et al,. BDDCS applied to over 900 drugs. AAPS J 2011; 13: 519-547.
73. Kasim NA, et al,. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004; 1: 85-96.
74. Joint Formulary Committee. British National Formulary. Vol. 62, London: Pharmaceutical Press, 2011.
75. Kearney AS, et al,. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res 1993; 10: 1461-1465. (Pubitemid 23302663)
76. Lennernas H, Fager G,. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32: 403-425. (Pubitemid 27199232)
77. Prueksaritanont T, et al,. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25: 1191-1199. (Pubitemid 27446590)
78. Brandstrom A, et al,. Structure activity relationships of substituted benzimidazoles. Scand J Gastroenterol Suppl 1985; 108: 15-22. (Pubitemid 15064507)
79. El-Badry M, et al,. Study of omperazole stability in aqueous solution: influence of cyclodextrins. J Drug Deliv Sci Tech 2009; 19: 347-351.
80. Shimamoto J, et al,. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. Eur J Clin Pharmacol 2000; 56: 65-68. (Pubitemid 30317784)
81. Willis JV, et al,. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 1979; 16: 405-410. (Pubitemid 10173752)
82. Brammer KW, et al,. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12 (Suppl. 3): S318-S326. (Pubitemid 20125727)
83. Demuria D, et al,. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother 1993; 37: 2187-2192.
84. Joe LA, et al,. Systemic absorption of oral fluconazole after gastrointestinal resection. J Antimicrob Chemother 1994; 33: 1070. (Pubitemid 24170917)
85. Hoffken G, et al,. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 1985; 27: 375-379. (Pubitemid 15144703)
86. Lettieri JT, et al,. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 1992; 36: 993-996.
87. Pratha VS, et al,. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults. Dig Dis Sci 2006; 51: 123-131. (Pubitemid 43106349)